Literature DB >> 2068765

Heterogeneity in the sensitivity of stocks and clones of Giardia to metronidazole and ornidazole.

A C Majewska1, W Kasprzak, J F De Jonckheere, E Kaczmarek.   

Abstract

The sensitivity in vitro to metronidazole and ornidazole of 7 stocks and of the cloned lines of 5 stocks of Giardia isolated from humans, rodents and monkeys was studied by the growth inhibition test. All 7 stocks of Giardia, irrespective of the host, differed in their sensitivity to these drugs, commonly used in therapy of human giardiasis. The differences were greater with ornidazole than with metronidazole. The 5 Giardia stocks from which clones were prepared were found to consist of populations with significantly (P less than 0.05) differing sensitivities to ornidazole and metronidazole. There was a positive correlation between high resistance in vitro to both drugs of all clones of one parent stock and treatment failures of giardiasis in the patient from which the parasite stock had been isolated. The spectra of sensitivity of Giardia to anti-giardial drugs may have implications concerning the suspected zoonotic character of human giardiasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2068765     DOI: 10.1016/0035-9203(91)90161-q

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  8 in total

1.  Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp.

Authors:  J A Upcroft; R W Campbell; K Benakli; P Upcroft; P Vanelle
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 2.  Treatment of giardiasis.

Authors:  T B Gardner; D R Hill
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

3.  Investigation of human giardiasis by karyotype analysis.

Authors:  S H Korman; S M Le Blancq; R J Deckelbaum; L H Van der Ploeg
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

4.  Comparison of Giardia isolates from different laboratories by isoenzyme analysis and recombinant DNA probes.

Authors:  W L Homan; F H van Enckevort; L Limper; G J van Eys; G J Schoone; W Kasprzak; A C Majewska; F van Knapen
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

5.  The old and new therapeutic approaches to the treatment of giardiasis: where are we?

Authors:  Haendel G N O Busatti; Joseph F G Santos; Maria A Gomes
Journal:  Biologics       Date:  2009-07-13

6.  High sensitivity of Giardia duodenalis to tetrahydrolipstatin (orlistat) in vitro.

Authors:  Juliane Hahn; Frank Seeber; Herbert Kolodziej; Ralf Ignatius; Michael Laue; Toni Aebischer; Christian Klotz
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

7.  Synthesis of novel hybrid molecules from precursors with known antiparasitic activity.

Authors:  Haythem A Saadeh; Ibrahim M Mosleh; Mohammad S Mubarak
Journal:  Molecules       Date:  2009-04-09       Impact factor: 4.411

8.  New synthesis and antiparasitic activity of model 5-aryl-1-methyl-4-nitroimidazoles.

Authors:  Haythem A Saadeh; Ibrahim M Mosleh; Mustafa M El-Abadelah
Journal:  Molecules       Date:  2009-07-27       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.